Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
about
Targeting the insulin growth factor receptor 1Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker AssessmentModulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectivesActivation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.Repression of liver colorectal metastasis by the serpin Spn4A a naturally occurring inhibitor of the constitutive secretory proprotein convertases.A novel antisense long noncoding RNA within the IGF1R gene locus is imprinted in hematopoietic malignancies.Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulationPersonalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.Identification of Novel IGF1R Kinase Inhibitors by Molecular Modeling and High-Throughput Screening.Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.The insulin receptor: a new target for cancer therapy.Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenograftsImpact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer.Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: clinical implications.A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factorsIGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insightsTargeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy.Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myelomaEndocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies.Potential dual role of KGF/KGFR as a target option in novel therapeutic strategies for the treatment of cancers and mucosal damages.Targeting the IGF-1R: The Tale of the Tortoise and the Hare.A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques.IFN-β is a potent inhibitor of insulin and insulin like growth factor stimulated proliferation and migration in human pancreatic cancer cells.Insulin-like growth factor-1 receptor inhibitors: a potential cancer treatment: patent highlight.Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma in vitro and in vivo.IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin.Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.Inhibition of the insulin-like growth factor-1 receptor enhances effects of simvastatin on prostate cancer cells in co-culture with bone.Function of insulin-like growth factor 1 receptor in cancer resistance to chemotherapy.An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor.
P2860
Q24633750-CABF79DC-A2E7-4199-A7FA-08DADC7AD299Q26798408-DD33688C-A6ED-4419-8162-D1A994DB0435Q26852578-F2BBF6BD-01CA-4A29-B34E-44E083174944Q30424348-F3714187-DC76-4D87-8804-665F4560607CQ34100905-C38BEECF-92FE-420F-B3CF-0FBDAB233DA5Q34115325-5DA5C6FE-7BA3-4471-9B33-D1F2BF45B3BCQ34387886-EAB3C67C-E915-4255-8E6D-2885EB722BA4Q34664129-EC094F2F-48D1-474A-82B1-39936B4C3486Q34704781-331320C6-20BA-49F3-9446-821E449B0212Q34789828-01E5458E-1F48-4470-A757-7B4937616CB2Q35603263-84DC41B3-95C5-46F8-9FD9-502D158FE79AQ35972002-9E8A930A-C9FF-4AD1-A080-88BD023697E6Q36084192-AF635353-65F7-4D77-AE25-90CDDE7610D3Q36456430-4BD13319-9F3B-48AB-B2F9-866BC58BFD5EQ36645661-2C29CA9E-F5DF-4123-A2FC-2FAA2E91D334Q37105231-7C526CE5-871E-45BC-B5C9-86F70028F04BQ37615933-54DA5595-839E-4BF6-886F-8457CF691C6EQ37975246-83F62A9B-AD2C-4CE3-A509-EA4047E5A469Q37986142-D827B161-CB0D-42D7-9D46-47C8B3465F30Q37992693-4EE39B76-B5D6-4E9C-9324-D751589FD0B4Q37996468-7664B763-1CE3-46C4-8E63-BE79F90E8560Q38474624-DA52C76D-FA6C-4019-8514-1CC43261AFB9Q38772200-2CEF5921-DE96-42FB-88E8-5B16CAF4FFA8Q38844045-2ED8C609-21CE-4E33-88F1-881F679BD329Q39779789-5FC682B2-2E95-4ACE-8F9D-EF9191212458Q42040539-EC065973-7586-4FFB-8566-D64EFEF8431BQ42322249-724D617B-856C-40FB-83D0-B16C58F209DFQ42579657-1A4346FE-30F9-476C-B619-C74E073C92B8Q42837186-D1ACDA62-26FE-4204-85AC-549BCB0DB72EQ47095382-7D2799C8-EF58-484E-8740-5A8478FFBBBAQ47956948-C32AA959-9D1E-4A37-8BC4-282E0B98A567
P2860
Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
@en
Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
@nl
type
label
Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
@en
Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
@nl
prefLabel
Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
@en
Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
@nl
P2860
P1476
Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
@en
P2093
Elizabeth Buck
Mark Mulvihill
P2860
P304
P356
10.1517/13543784.2011.558501
P407
P577
2011-03-30T00:00:00Z